CD200R1 and multiple sclerosis: Efforts to augment CD200R inhibitory function using a recombinant version of the ligand, CD200 fragment crystallizable (Fc)17, or an antibody18 in mice have demonstrated that activating CD200R suppresses disease activity in experimental multiple sclerosis and autoimmune-mediated uveoretinitis models.